Investigation of intravenous dexmedetomidine administration effect on patency of arteriovenous fistula in patients undergoing arteriovenous fistula creation surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210807052098N1

Enrollment

Registered

2021-10-19

Start date

2021-11-11

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: renal failure. Condition 2: dexmedetomidine. Condition 3: arteriovenous fistula.

Interventions

Intervention 1: Intervention group: Injection of 1 µg per kg body weight of dexmedetomidine over ten min and then infusion of dexmedetomidine at a concentration of 0.5 µg / kg per hour. Intervention 2

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients with renal failure and dependent on dialysis candidate for arteriovenous fistula surgery without heart failure non smoker age below eighty years

Exclusion criteria

Exclusion criteria: The patient's unwillingness to participate in the study at any time during the study Contraindications for the use of dexmedetomidine: severe heart block, severe bradycardia, severe heart failure, QT changes, hypotension, liver failure, intravascular volume depletion, allergy to alpha 2 agonists smoking age over 80 years heart failure

Design outcomes

Primary

Measure	Time frame
Patency rate of arteriovenous fistula. Timepoint: after surgery and one month later. Method of measurement: clinical examination by surgeon.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Hoseini Amini

Ghoum University of Medical Sciences

hoseini.amini@gmail.com+98 991 204 3747

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026